Literature DB >> 31020430

Effect of Grapefruit Juice Intake on Serum Level of the Endogenous CYP3A4 Metabolite 4β-Hydroxycholesterol-an Interaction Study in Healthy Volunteers.

Caroline Gjestad1, Kristine Hole2, Tore Haslemo2, Ulf Diczfalusy3, Espen Molden2,4.   

Abstract

4β-Hydroxycholesterol (4βOHC) is an endogenous CYP3A4 metabolite. However, it is unclear whether circulating levels of 4βOHC may reflect hepatic CYP3A4 activity or both hepatic and intestinal enzyme activity. The aim of this study was to investigate the effect of grapefruit juice, regarded to be a selective intestinal CYP3A4 inhibitor, on serum 4βOHC levels in healthy volunteers. The participants (n = 22) consumed grapefruit juice twice daily for 3 weeks followed by a 2-week washout period. Blood samples for measurements of 4βOHC and the non-CYP3A4-derived oxysterols 24-hydroxycholesterol (24OHC) and 27-hydroxycholesterol (27OHC), as well as lathosterol and total cholesterol, were drawn on days 0, 7, 21, and 35. Median individual changes (ratios) in cholesterol-corrected 4βOHC levels from baseline to weeks 1, 3, and 5 were 0.94 (P = 0.2), 0.98 (P = 0.3), and 0.97 (P = 0.9), respectively. In comparison, median changes (ratios) in cholesterol-corrected levels of 24OHC at the same points were 1.01 (P = 0.6), 0.98 (P = 0.3), and 0.99 (P = 0.5), and of 27OHC 1.01 (P = 0.8), 0.97 (P = 0.5), and 0.99 (P = 0.2). Surprisingly, serum concentration of cholesterol was significantly reduced by approximately 5% after 1 week (P = 0.03), while median cholesterol-corrected levels of lathosterol increased significantly and persistently by approximately 15% during the whole 5-week period (P < 0.04). In conclusion, the present findings suggest that intestinal CYP3A4 is not relevant for the overall formation of 4βOHC in healthy volunteers. The fact that grapefruit juice altered cholesterol homeostasis should be further investigated.

Entities:  

Keywords:  4β-hydroxycholesterol; CYP3A4; grapefruit juice; oxysterols

Year:  2019        PMID: 31020430     DOI: 10.1208/s12248-019-0330-1

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  43 in total

Review 1.  Drug metabolism and variability among patients in drug response.

Authors:  Grant R Wilkinson
Journal:  N Engl J Med       Date:  2005-05-26       Impact factor: 91.245

2.  Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?

Authors:  Sibylle Neuhoff; Geoffrey T Tucker
Journal:  Br J Clin Pharmacol       Date:  2018-02-21       Impact factor: 4.335

3.  Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.

Authors:  Linda Björkhem-Bergman; Tobias Bäckström; Hanna Nylén; Yuko Rönquist-Nii; Eva Bredberg; Tommy B Andersson; Leif Bertilsson; Ulf Diczfalusy
Journal:  Drug Metab Pharmacokinet       Date:  2014-02-11       Impact factor: 3.614

4.  4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?

Authors:  Caroline Gjestad; Duy Khanh Huynh; Tore Haslemo; Espen Molden
Journal:  Br J Clin Pharmacol       Date:  2015-12-26       Impact factor: 4.335

5.  Genetic predictors of interindividual variability in hepatic CYP3A4 expression.

Authors:  Vishal Lamba; John C Panetta; Stephen Strom; Erin G Schuetz
Journal:  J Pharmacol Exp Ther       Date:  2009-11-24       Impact factor: 4.030

6.  Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study.

Authors:  Chang Liu; Ya-Fei Shang; Xu-Feng Zhang; Xiao-Gang Zhang; Bo Wang; Zheng Wu; Xue-Min Liu; Liang Yu; Feng Ma; Yi Lv
Journal:  Eur J Clin Pharmacol       Date:  2009-07-21       Impact factor: 2.953

Review 7.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

8.  Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.

Authors:  Thomas Vanhove; Hylke de Jonge; Henriëtte de Loor; Pieter Annaert; Ulf Diczfalusy; Dirk R J Kuypers
Journal:  Br J Clin Pharmacol       Date:  2016-09-20       Impact factor: 4.335

9.  Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.

Authors:  K P Kanebratt; U Diczfalusy; T Bäckström; E Sparve; E Bredberg; Y Böttiger; T B Andersson; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  2008-07-23       Impact factor: 6.875

10.  White and colored grapefruit juice produce similar pharmacokinetic interactions.

Authors:  Y Uesawa; M Abe; K Mohri
Journal:  Pharmazie       Date:  2008-08       Impact factor: 1.267

View more
  2 in total

1.  Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range.

Authors:  Kine Eide Kvitne; Kristine Hole; Veronica Krogstad; Birgit Malene Wollmann; Christine Wegler; Line K Johnson; Jens K Hertel; Per Artursson; Cecilia Karlsson; Shalini Andersson; Tommy B Andersson; Rune Sandbu; Jøran Hjelmesæth; Eva Skovlund; Hege Christensen; Rasmus Jansson-Löfmark; Anders Åsberg; Espen Molden; Ida Robertsen
Journal:  Eur J Clin Pharmacol       Date:  2022-06-01       Impact factor: 3.064

2.  Response to: "Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time".

Authors:  Kine Eide Kvitne; Kristine Hole; Espen Molden; Ida Robertsen
Journal:  Eur J Clin Pharmacol       Date:  2022-09-13       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.